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ABSTRACT  
Objective: A highly specific, sensitive and rapid HPLC-MS/MS method has been developed and validated for the simultaneous quantification of 
bisoprolol and enalapril in the present of enalaprilat in human plasma.  
Methods: Analytes were extracted from plasma using a protein precipitation extraction method. Chromatography was achieved on Discovery C18, 
50 × 2.1 mm, 5 μm column. Samples were chromatographed in a gradient mode (eluent A (acetonitrile-water–formic acid, 5: 95: 0.1 v/v), eluent B 
(acetonitrile–formic acid, 100: 0.1 v/v)). The initial content of the eluent B is 0%, which increases linearly by 1.0 min to 100% and to 1.01 min 
returns to the initial 0%. The mobile phase was delivered at a flow rate of 0.400 ml/min into the mass spectrometer ESI chamber. The sample 
volume was 5 μl.  
Results: The total chromatographic run time was 2.0 min and the elution of bisoprolol, enalapril, enalaprilat and IS (verapamil) occurred at ~1.01, 
1.03, 0.96 and 1.09 min, respectively. A linear response function was established at 0.5-50 ng/ml for bisoprolol fumarate, 2-200 ng/ml for enalapril 
maleate, 1-100 ng/ml for enalaprilat dehydrate in human plasma. The intraday and interday accuracy and precisions were in the range of 0.311 %-
0.647 % and 0.364 %-0.572 % for bisoprolol, 0.321 %-0.747 % and 0.390 %-0.673 % for enalapril, 0.221 %-0.547 % and 0.264 %-0.773 % for 
enalaprilat, respectively.  
Conclusion: A new rapid method was developed for simultaneous determination of bisoprolol and enalapril in the present of enalaprilat in human 
plasma. The method was strictly validated according to the ICH guidelines. The information thus obtained from the study can be used for the full 
pharmacokinetic profiling in individuals.  
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Bisoprolol is a synthetic, β1-selective (cardioselective) adrenoceptor 
blocking agent without significant membrane stabilizing activity or 
intrinsic sympathomimetic activity in its therapeutic dosage range. 
The chemical name of bisoprolol fumarate is 1-{4-[(2-
isopropoxyethoxy) methyl] phenoxy}-3-(isopropyl amino) propan-
2-ol (fig. 1) [1]. 
Enalapril maleate is chemically described as (2S)-1-[(2S)-2-[[(1S)-1-
(Ethoxycarbonyl)-3-phenylpropyl] amino] propanoyl] pyrrolidine-2-
carboxylic acid (Z)-butenedioate (fig. 2). Enalapril maleate is a 
prodrug which metabolized rapidly in the liver to ethyl ester of a 
long-acting enalaprilat (fig. 3) which inhibits angiotensin-converting 
enzyme (ACE) in human subjects and animals [2]. 
 
 
Fig. 1: Chemical structure of bisoprolol fumarate 
 
Fig. 2: Chemical structure of enalapril maleate 
 
 
Fig. 2: Chemical structure of enalaprilat 
 
In the contemporary literature, few bioanalytical methods were reported 
for quantification of bisoprolol. Dinga et al. reported an LC-electrospray 
ionization (ESI)-MS for determination of bisoprolol in human plasma. 
Plasma aliquots were processed using ethyl acetate liquid-liquid 
extraction method. Chromatographic separation of bisoprolol was 
achieved on ZORBAX SB-C18 column using gradient elution. The 
linearity range for bisoprolol in plasma was found to be 0.05-120 ng/ml. 
Total run time for this analysis was 5.0 min [3]. Similarly, Bhatt et al. 
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reported the determination of bisoprolol in human plasma by an LC-ESI-
MS method. Plasma aliquots were processed using solid phase extraction 
methodology. Chromatographic separation of bisoprolol was achieved 
on BetaBasic 8 column using an isocratic elution. The linearity range was 
0.5-70 ng/ml for bisoprolol in plasma [4]. Recently, Liu et al. reported a 
liquid chromatography-tandem mass spectrometric (LC-MS/MS) 
method for the quantitation of bisoprolol in human plasma with a 
linearity range of 0.5-100 ng/ml. Plasma aliquots spiked with bisoprolol 
were processed using simple protein precipitation extraction method [5] 
followed by chromatographic separation of bisoprolol achieved on 
Capcell Pak C18 MG III column (100 mm × 2.0 mm, 5 μ), using gradient 
elution. Similarly, Hemavanthi G. et al. reported an LC-electrospray 
ionization (ESI)-MS for determination of bisoprolol and triamterene in 
human plasma. Chromatographic separation of bisoprolol was achieved 
on Welchrom XB C18, 50 × 4.6 mm0, 5 μm column using an isocratic 
mobile phase (2 mmol ammonium formate: acetonitrile, 70:30 v/v) at a 
flow rate of 0.60 ml/min. A linear response function was established at 
2.04-210 ng/ml for both the analytes in human plasma. Total run time 
for this analysis was 3.5 min [6].  
Bisoprolol fumarate can be determined by various methods such as 
ultraviolet, reverse phase high-performance LC (HPLC), LC-MS/MS, and 
high-performance thin-layer chromatography. Methods have been 
reported for analysis of bisoprolol fumarate in mono-or in combination 
with other drugs in pharmaceutical formulations [7-11]. From the 
literature survey, it is very clear that no method has been reported for 
simultaneous determination of bisoprolol and enalapril in the present of 
enalaprilat in human plasma by LC-MS/MS. As for quantification, LC-
MS/MS seems to be more sensitive and precise for the simultaneous 
determination of bisoprolol and enalapril in the present of enalaprilat in 
human plasma. The proposed method is validated as per guidelines [12].  
MATERIALS AND METHODS  
Chemicals and reagents  
Bisoprolol (purity 100.0 %), enalapril (purity 99.3 %), enalaprilat 
(purity 100.0 %), verapamil (Internal Standard) (purity 99.9 %) 
were purchased from Moehs Catalana, S. L., Spain, Zhejiang Huahai 
Pharmaceutical Co., Ltd, КНР, EDQM–Council of Europe. HPLC grade 
acetonitrile and methanol were purchased from CHROMASOLV, 
HPLC grade formic acid was purchased from Fluka. All other 
chemicals and reagents were of analytical grade. Microcaps® 
disposable micropipettes (50 μl, catalog number: 1-000-0500) were 
purchased from Drummond Scientific Company, USA. The control 
human dipotassium ethylenediaminetetraacetic acid (K2EDTA) 
plasma sample was procured from Red Cross Society, Ukraine.  
Instrumentation and chromatographic conditions  
A Shimadzu HT (Shimadzu, Japan) LC system equipped with 
degasser (DGU-14A), binary pump (LC-20ADXR) along with auto-
sampler (SIL-20ACXR) was used to inject 5 μl aliquots of the 
processed samples on Discovery C18, 50 × 2.1 mm, 5 μm column 
maintained at 25±1 °C. Samples were chromatographed in a gradient 
mode (eluent A (acetonitrile-water–formic acid, 5: 95: 0.1 v/v), 
eluent B (acetonitrile–formic acid, 100: 0.1 v/v)). The initial content 
of the eluent B is 0%, which increases linearly by 1.0 min to 100% 
and to 1.01 min returns to the initial 0%. The mobile phase was 
delivered at a flow rate of 0.400 ml/min into the mass spectrometer 
ESI chamber. Parameters of electrospray ionizer and MRM 
parameters are listed in table 1-2. The analytical data were 
processed by analyst software (version 1.5.2). 
  
Table 1: Parameters of ionizer electrospray 
 Parametr Value 
1 Polarity Positive 
2 Nebulizer Gas (NEB, Gas 1) 15 
3 Curtain Gas (CUR) 8 
4 Collision Gas (CAD) 4 
5 IonSpray Voltage (IS) 5000 
6 Temperature (TEM) 400 
7 Turbo IonSpray Gas 8 
8 Horizontal Position 5.3 
9 Lateral Position 1.3 
 
Table 2: Multiple reaction monitoring (MRM) parameters 
ID Parent, m/z Daughter, m/z Time, ms DP, V FP, V EP, V CE, V CXP, V 
Enalapril 377.397 234.3 50 41 210 11 29 20 
Enalaprilat 349.328 206.3 50 46 220 11 27 34 
Bisoprolol 326.435 116.3 50 46 260 11 27 20 
Verapamil (IS) 455.385 165.4 50 61 320 11 39 28 
 *Abbreviations: DP, declustering potential; FP, focusing potential; EP, entrance potential; CE, collision energy; CXP, collision cell exit potential 
 
Standard solutions  
Bisoprolol, enalapril, enalaprilat and IS have weighed accurately into 
volumetric flasks using an analytical microbalance. Approximately 1 
mg/ml primary stock solutions of enalaprill, 0.5 mg/ml primary stock 
solutions of enalaprilat, 0.25 mg/ml primary stock solutions of 
bisoprolol and 0.5 mg/ml primary stock solutions of verapamil (IS) 
solutions were prepared in methanol. The stock solutions were stored 
at −20 °C, which was found to be stable for 1 mo. The stock solutions of 
bisoprolol, enalapril, enalaprilat were successively diluted with 
methanol and water to prepare secondary stocks and working 
solutions. Secondary stock solutions and working solutions were used 
to prepare calibration curve (CC) and quality control (QC) samples. 
Working stock solutions were stored at 4 °C for a week. Working 
stocks were used to prepare plasma calibration standards. A working 
IS solution (20 ng/ml) was prepared in acetonitrile: methanol (50:50 
v/v). Blank human plasma was screened before spiking to ensure that 
it was free from endogenous interference at retention times of 
bisoprolol, enalapril, enalaprilat and IS, respectively. Calibration 
standards’ samples (0.5-50 ng/ml for bisoprolol fumarate, 2-200 
ng/ml for enalapril maleate, 1-100 ng/ml for enalaprilat dehydrate) 
were prepared by spiking the blank human K2EDTA plasma with 
appropriate concentration of bisoprolol, enalapril and enalaprilat.  
Samples for the determination of precision and accuracy were 
prepared by spiking control human plasma in bulk with bisoprolol, 
enalapril and enalaprilat at appropriate concentrations (for 
bisoprolol fumarate 1.5 ng/ml low QC [LQC], 15.0 ng/ml medium QC 
[MQC], and 37.5 ng/ml high QC [HQC], for enalapril maleate 6.0 
ng/ml low QC [LQC], 60.0 ng/ml medium QC [MQC], and 150.0 
ng/ml high QC [HQC], for enalaprilat dihydrate 3.0 ng/ml low QC 
[LQC], 30.0 ng/ml medium QC [MQC], and 75.0 ng/ml high QC 
[HQC],) and 120 μL plasma aliquots were distributed into different 
tubes. All the samples were stored at −80 °C±10 °C.  
Sample preparation  
A simple protein precipitation extraction method was followed for 
extraction of bisoprolol, enalapril, enalaprilat at from human plasma. 
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From the deep freezer, the required quantities of CC standards and 
QC samples were withdrawn. The samples were thawed at room 
temperature. To an aliquot of 100 μl plasma, 20 μl of IS was added. 
To this mixture, 300 μl of acetonitrile: methanol (50:50 v/v) was 
added and vortexed for 2 min, followed by centrifugation at 6000 
rpm for 5 min at 4 °C. After centrifugation, approximately 50 μl 
supernatant was aliquoted into, respectively, labeled autosampler 
vials, which were later placed in the autosampler at 15 °C±4 °C. 10 μl 
of the sample was injected onto LC-MS/MS system for analysis. 
Method validation 
A full validation according to the ICH guidelines [12] was performed 
for the assay in K2EDTA human plasma. 
Specificity and selectivity 
The specificity of the method was evaluated by analyzing human plasma 
samples from different lots to investigate the potential interferences at 
the chromatographic peak region for analytes and IS. The acceptance 
criterion for the experiment was that should have<20% area response to 
that of the LLOQ level response in the same matrix. Two lots of 
hemolyzed plasma samples were also analyzed to ensure specificity 
against potential biological interferences. 
Linearity  
The points CC (0.5-50 ng/ml for bisoprolol fumarate, 2-200 ng/ml for 
enalapril maleate, 1-100 ng/ml for enalaprilat dehydrate) were 
constructed by plotting the peak area ratio of each analyte: IS against 
the nominal concentration of calibration standards in K2EDTA human 
plasma. Following the evaluation of different weighing factors, the 
results were fit into linear regression analysis using 1/X2 (X: 
Concentration) weighing factor. The CC should have a correlation 
coefficient (r) of 0.99 or better. The acceptance criteria for each back-
calculated standard concentration were±15% deviation from the 
nominal value except at LLOQ, which was set at±20%. 
Recovery 
The efficiency of bisoprolol, enalapril,enalaprilat, and IS extraction 
from human plasma was determined by comparing the responses of 
the analytes extracted from replicate QC samples (n=6) with those of 
neat standard solutions spiked in post-extracted plasma blank 
sample at equivalent concentrations by protein precipitation 
extraction method. Recovery of enalapril was determined at LQC 
(6.28 ng/ml) and HQC (150.00 ng/ml) concentrations, enalaprilat 
was determined at LQC (2.99 ng/ml) and HQC (75.8 ng/ml) 
concentrations, bisoprolol was determined at LQC (1.51 ng/ml) and 
HQC (36.7 ng/ml) concentrations whereas the recovery of IS was 
determined at a single concentration of 20 ng/ml. 
Matrix effect 
The effect of human plasma constituents over the ionization of 
bisoprolol, enalapril, enalaprilat, and IS was determined by post-
column infusion method to evaluate matrix effect. Briefly, an infusion 
pump delivers a constant amount of analyte into LC system outlet 
entering to mass spectrometer inlet. To follow the analyte signal, the 
mass spectrometer was operated in MRM mode. The human plasma 
constituent sample extract was injected on LC column. A steady ion 
response was obtained as a function of time since the analyte was 
infused at a constant rate. Any endogenous compound that elutes from 
the column which causes a variation in ESI response of the infused 
analyte was seen as a suppression or enhancement in the response of 
the infused analyte. A separate experiment was performed with 
bisoprolol, enalapril, enalapril, and IS solutions, which were infused at 
a constant rate, and blank matrix sample injected through the LC. To 
evaluate matrix effect, different lots of human plasma were spiked 
with analyte concentration levels at LQC and HQC levels. According to 
guidelines, the acceptance criterion for each back-calculated 
concentration was±15% deviation from the nominal value. 
Precision and accuracy 
The intra-assay precision and accuracy were estimated by analyzing 
six replicates containing bisoprolol, enalapril, enalapril, at four 
different QC levels concentrations (for bisoprolol fumarate 1.5 
ng/ml low QC [LQC], 15.0 ng/ml medium QC [MQC], and 37.5 ng/ml 
high QC [HQC], for enalapril maleate 6.0 ng/ml low QC [LQC], 60.0 
ng/ml medium QC [MQC], and 150.0 ng/ml high QC [HQC], for 
enalaprilat dihydrate 3.0 ng/ml low QC [LQC], 30.0 ng/ml medium 
QC [MQC], and 75.0 ng/ml high QC [HQC]) in human plasma. The 
four-level QC samples on four different runs were performed to 
assess the interassay precision. The acceptance criteria for each 
back-calculated standard concentration were 85-115% accuracy 
from the nominal value except at LLOQ, which was set at 80-120%. 
Stability experiments 
Stability tests were conducted to evaluate the stability of bisoprolol, 
enalapril, enalaprilat in plasma samples under different conditions. 8 h 
bench top stability, processed samples stability (autosampler stability for 
26 h at 10 °C), three cycles of freeze-thaw stability, 30 d of long-term 
stability at −80±10 °C were performed at LQC and HQC levels using six 
replicates at each level. Samples were considered stable if assay values’ 
acceptance criterion was of accuracy (i.e., 85-115% from fresh samples) 
and precision (i.e.,±15% relative standard deviation [RSD]). 
RESULTS AND DISCUSSION 
LC separation of bisoprolol and IS has been carried out using various 
mobile phases consisting of different aqueous solutions and 
methanol or acetonitrile as the organic phase. Hernando et al. [13] 
used acetonitrile as an organic mobile phase to achieve shorter 
retention times and better resolution of bisoprolol and IS. The 
formic acid solution as an additive in water was used by Li et al. [14-
16] to improve the sensitivity of MS detection. 
In the present study, optimization and critical evaluation of mobile 
phase composition (gradient), flow rate, and analytical column were 
important to obtain good resolution of peaks of interest from the 
endogenous components, which in turn affect reproducibility and 
sensitivity of the method. Selection of chromatographic conditions 
for the proposed method was optimized to suit the preclinical 
pharmacokinetic studies. To ease the sample preparation in 
microtubes and to reduce the usage of solvent, the plasma volume 
was kept low. Initial feasibility experiments of a various mixture(s) 
of solvents such as acetonitrile, methanol and formic acid along with 
altered flow rates (in the range of 0.1-0.6 ml/min) were performed 
to optimize an effective chromatographic resolution of bisoprolol, 
enalapril, enalaprilat, and IS. Various analytical columns were tested 
to obtained good and reproducible response within short run time. 
The resolution of peaks was best achieved with Discovery C18, 50 × 
2.1 mm, 5 μm column. Samples were chromatographed in a gradient 
mode (eluent A (acetonitrile-water–formic acid, 5: 95: 0.1 v/v), 
eluent B (acetonitrile–formic acid, 100: 0.1 v/v)). The initial content 
of the eluent B is 0%, which increases linearly by 1.0 min to 100% 
and to 1.01 min returns to the initial 0%. The mobile phase was 
delivered at a flow rate of 0.400 ml/min into the mass spectrometer 
ESI chamber. The injection volume was 5 μl.  
The purpose of sample extraction optimization is mainly to achieve 
high extraction recovery with negligible or low matrix effects to 
improve sensitivity and reliability of LC-MS/MS analysis. A poor 
extraction procedure decreases method robustness due to the 
presence of endogenous interference in the sample extracts, which are 
not efficiently cleaned up due to poor extraction procedure decreases 
the method robustness due to the endogenous interference in the 
sample extracts. With time-saving advantage and simplicity, the 
protein precipitation extraction method was chosen as an extraction 
method. The attained LLOQ was sufficient to quantify bisoprolol, 
enalapril, enalaprilat in low-dose pharmacokinetic studies. 
Bisoprolol, enalapril, enalaprilat eluted at ~1.01, 1.03 and 0.96 min, 
respectively. During a direct infusion experiment, the mass spectra 
for bisoprolol, enalapril, enalaprilat and IS revealed peaks at m/z 
326.435, 377.397, 349.328 and 455.385, respectively as protonated 
molecular ions, [M+H]+. Typical multiple reaction monitoring 
chromatograms of bisoprolol, enalapril, enalaprilat and internal 
standard in dipotassium ethylenediaminetetraacetic acid human 
blank plasma are shown in fig. 4-5. 
In the previous study, chromatographic separation of bisoprolol 
was achieved on Welchrom XB C18, 50 × 4.6 mm0, 5 μm column 
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using an isocratic mobile phase (2 mmol ammonium formate: 
acetonitrile, 70:30 v/v) at a flow rate of 0.60 ml/min. A linear 
response function was established at 2.04-210 ng/ml for analytes 
in human plasma. Total run time for this analysis was 3.5 min [6]. 




Fig. 4: Typical multiple reaction monitoring chromatograms of bisoprolol (right up panel), enalapril (left up panel), enalaprilat (left down 
panel) and internal standard (right down panel) in dipotassium ethylenediaminetetraacetic acid human blank plasma 
 
 
Fig. 5: Typical multiple reaction monitoring chromatograms of bisoprolol (right up panel), enalapril (left up panel), enalaprilat (left down 
panel) and internal standard (right down panel) in dipotassium ethylenediaminetetraacetic acid human blank plasma 
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The total chromatographic run time was 2.0 min and the elution of 
bisoprolol, enalapril, enalaprilat and IS (verapamil) occurred at 
~1.01, 1.03, 0.96 and 1.09 min, respectively.  
Specificity 
Different lots of plasma were analysed to ensure that no endogenous 
interferences were present at the retention time of bisoprolol, 
enalapril, enalaprilat. LLOQ level samples along with plasma blank 
from the respective plasma lots were prepared and analysed (table 3). 
Linearity 
The calibration standard curves had a reliable reproducibility over the 
standard concentrations across the calibration range. The average 
regression (n=3) was found to be>0.997 for all analytes. 
 
Table 3: Results of specificity for bisoprolol, enalapril, enalaprilat 
S. No. Enalapril Enalaprilat Bisoprolol 
STD BL LLOQ % interference STD BL LLOQ % interference STD BL LLOQ % interference 
Area RT Area RT Area RT 
1 0 2190 1.03 NIL 0 394 0.97 NIL 0 557 1.01 NIL 
2 0 2208 1.03 NIL 0 420 0.96 NIL 0 563 1.01 NIL 
3 0 2098 1.03 NIL 0 394 0.97 NIL 0 570 1.01 NIL 
4 0 2190 1.03 NIL 0 394 0.97 NIL 0 557 1.01 NIL 
5 0 2190 1.03 NIL 0 503 0.96 NIL 0 554 1.01 NIL 
6 0 2208 1.04 NIL 0 379 0.98 NIL 0 558 1.01 NIL 
7 0 2098 1.03 NIL 0 382 0.96 NIL 0 551 1.01 NIL 
8 0 2126 1.03 NIL 0 379 0.97 NIL 0 547 1.01 NIL 
9 0 2190 1.03 NIL 0 501 0.97 NIL 0 543 1.01 NIL 
10 0 2224 1.03 NIL 0 420 0.97 NIL 0 547 1.01 NIL 
*Average of triplicate injections, In all plasma blanks, the response at the retention time of bisoprolol, enalapril, enalaprilat was less than 20% of 
LLOQ response and at the retention time of IS, the response was less than 5% of mean IS response in LLOQ.  
 
Lin AP EpBp 041017.rdb (Ep): "Linear" Regression ("1 / x" weighting): y = 0.0185 x + -0.00151 (r = 0.9997)
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Fig. 6: The calibration curve of enalapril maleate in human plasma 
 
The calibration curve (fig. 6) (peak area ratio Vs Concentration) was 
linear over working range for enalapril maleate of 2 to 200.00 ng/ml 
with 7 point calibration used for quantification by linear regression, 
shown in fig. 6. The regression equation for the analysis was 
Y=0.0185x+0.00151 with coefficient of correction (r2) = 0.9997. 
The calibration curve (fig. 7) (peak area ratio Vs Concentration) was 
linear over working range for enalaprilat dihydrate of 1 to 100.00 ng/ml 
with 7 point calibration used for quantification by linear regression, 
shown in fig. 7. The regression equation for the analysis was 
Y=0.00732x+0.000198 with coefficient of correction (r2) = 0.9998. 
The calibration curve (fig. 8) (peak area ratio Vs Concentration) was 
linear over working range for bisoprolol fumarate of 0.5 to 50.00 
ng/ml with 7 point calibration used for quantification by linear 
regression, shown in fig. 8. The regression equation for the analysis 
was 
Y=0.0195x+0.000763 with coefficient of correction (r2) = 0.9997. 
In the previous study, a linear response function was established at 
2.04-210 ng/ml for bisoprolol in human plasma. [6]. In the present 
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study, a linear response function was established at 0.5-50 ng/ml for 
bisoprolol fumarate, 2-200 ng/ml for enalapril maleate, 1-100 ng/ml 
for enalaprilat dehydrate in human plasma. 
Recovery 
The % mean recovery for bisoprolol, enalapril, enalaprilat in LQC, 
MQC and HQC are listed in tables 4-6. 
 
Lin AP EpBp 041017.rdb (Et): "Linear" Regression ("1 / x" weighting): y = 0.00732 x + 0.000198 (r = 0.9998)
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Fig. 7: The calibration curve of enalaprilat dihydrate in human plasma 
 
Lin AP EpBp 041017.rdb (Bp): "Linear" Regression ("1 / x" weighting): y = 0.0195 x + -0.000763 (r = 0.9997)
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Fig. 8: The calibration curve of bisoprolol fumarate in human plasma 
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Table 4: The % mean recovery of enalapril for LQC, MQC and HQC 
S. No. LQC MQC HQC 
1 6.03 62.9 154 
2 6.37 58.8 142 
3 5.86 58.9 144 
4 6.91 63.3 153 
5 6.22 60.6 159 
Mean 6.28 60.9 150 
SD 0.402 2.14 7.16 
% CV 6.4 3.5 4.8 
% Mean Recovery 104.6 101.5 100.3 
*Abbreviations: Lower quality control (LQC), middle-quality control (MQC), higher quality control (HQC), Each value is represented as a mean±SD 
of 5 observations (n=5), SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 5: The % mean recovery of enalaprilat for LQC, MQC and HQC 
S. No. LQC MQC HQC 
1 3.00 31.2 78.6 
2 2.89 27.6 73.9 
3 3.04 28.4 73.4 
4 3.09 30.7 76.2 
5 2.93 31.3 77.1 
Mean 2.99 29.8 75.8 
SD 0.081 1.72 2.18 
% CV 2.7 5.8 2.9 
% Mean Recovery 99.7 99.4 101.1 
*Abbreviations: Lower quality control (LQC), middle-quality control (MQC), higher quality control (HQC), Each value is represented as a mean±SD 
of 5 observations (n=5), SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 6: The % mean recovery of bisoprolol for LQC, MQC and HQC 
S. No. LQC MQC HQC 
1 1.51 15.1 37.3 
2 1.57 15.9 34.6 
3 1.46 14.8 35.6 
4 1.42 15.6 36.9 
5 1.57 15.3 39.1 
Mean 1.51 15.3 36.7 
SD 0.067 0.43 1.72 
% CV 4.4 2.8 4.7 
% Mean Recovery 100.4 102.3 97.9 
*Abbreviations: Lower quality control (LQC), middle-quality control (MQC), higher quality control (HQC), Each value is represented as a mean±SD 
of 5 observations (n=5), SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
The % mean recovery for enalapril in LQC, MQC and HQC was 104.6 
%, 101.5 % and 100.3 %, for enalaprilat in LQC, MQC and HQC was 
99.7 %, 99.4 % and 101.1 %, for bisoprolol in LQC, MQC and HQC 
was 100.4 %, 102.3 % and 97.9 % respectively. 
Intraday (within run) and Inter-day (between run) precision 
and accuracy 
The within-run coefficients of variation ranged between 0.311 % 
and 0.647 % for bisoprolol. The within-run percentages of nominal 
concentrations ranged between 99.82 % and 100.82 % for 
bisoprolol. The between-run coefficients of variation ranged 
between 0.364 % and 0.572 % for bisoprolol. The between-run 
percentages of nominal concentrations ranged between 99.27 % and 
100.76 % for bisoprolol. Results are presented in table 7. The assay 
values on both the occasions (intra-and inter-day) were found to be 
within the accepted limits. 
The within-run coefficients of variation ranged between 0.321 % 
and 0.747 % for enalapril. The within-run percentages of nominal 
concentrations ranged between 99.93 % and 101.31 % for enalapril. 
The between-run coefficients of variation ranged between 0.390 % 
and 0.673 % for enalapril. The between-run percentages of nominal 
concentrations ranged between 99.47 % and 102.76 % for enalapril. 
Results are presented in table 8. 
 
Table 7: Intra-day and Inter-day precision data of bisoprolol 
Day Intra-day precision Inter-day precision 
Mean R. S. D. % Mean R. S. D. % 
1 99.82 0.311 100.76 0.364 
2 100.41 0.647 99.27 0.390 
3 100.82 0.336 100.53 0.572 
*Each value is represented as a mean±SD of observations, SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0 
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Table 8: Intra-day and Inter-day precision data of enalapril 
Day Intra-day precision Inter-day precision 
Mean R. S. D. % Mean R. S. D. % 
1 99.93 0.321 102.76 0.564 
2 101.31 0.747 99.47 0.390 
3 100.82 0.376 100.13 0.673 
*Each value is represented as a mean±SD of observations, SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0 
 
Table 9: Intra-day and Inter-day precision data of enalaprilat 
Day Intra-day precision Inter-day precision 
Mean R. S. D. % Mean R. S. D. % 
1 99.13 0.221 100.16 0.264 
2 100.31 0.547 99.87 0.490 
3 100.62 0.336 101.33 0.773 
*Each value is represented as a mean±SD of observations, SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0 
 
The within-run coefficients of variation ranged between 0.221 % 
and 0.547 % for enalaprilat. The within-run percentages of nominal 
concentrations ranged between 99.13 % and 100.62 % for 
enalaprilat. The between-run coefficients of variation ranged 
between 0.264 % and 0.773 % for enalaprilat. The between-run 
percentages of nominal concentrations ranged between 99.87 % and 
101.33 % for enalaprilat. Results are presented in table 9. 
In the previous study, the intraday and interday accuracy and 
precisions were in the range of 1.12-7.87% and 1.26-6.36% and 
1.46-6.13% and 1.65-7.34% for bisoprolol and triamterene, 
respectively [6]. In the present study, the intraday and interday 
accuracy and precisions were in the range of 0.311 %-0.647 % and 
0.364 %-0.572 % for bisoprolol, 0.321 %-0.747 % and 0.390 %-
0.673 % for enalapril, 0.221 %-0.547 % and 0.264 %-0.773 % for 
enalaprilat, respectively. The assay values the occasions (intra-and 
inter-day) were found to be within the accepted limits. 
Matrix effect 
The lowest concentration with the RSD<20% was taken as LLOQ and 
was found to be 2.19 ng/ml for enalapril, 1.01 ng/ml for enalaprilat, 
0.585 ng/ml for bisoprolol.  
The % accuracy of LLOQ samples prepared with the different 
biological matrix lots was found 109.5 % for enalapril, 101.1 % for 
enalaprilat, 117.1 % for bisoprolol, which were found within the 
range of 80.00-120.00% for the seven different plasma lots. % CV for 
LLOQ samples was observed as 3.1%, 12.0 %, 7.0 % respectively, 
which are within 20.00% of the acceptance criteria. Results are 
presented in tables 10-12. 
 
Table 10: Results of matrix effect of enalapril 








% CV 3.1 
% Mean recovery 109.5 
* Abbreviations: Lower limit of quantification (LLOQ), Each value is represented as a mean±SD of 5 observations (n=5), SD: Standard Deviation, 
RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 11: Results of matrix effect of enalaprilat 








% CV 12.0 
% Mean recovery 101.1 
* Abbreviations: Lower limit of quantification (LLOQ), Each value is represented as a mean±SD of 5 observations (n=5), SD: Standard Deviation, 
RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Stability 
The predicted concentrations for bisoprolol (1.51 ng/ml and 36.7 
ng/ml), enalapril (6.28 ng/ml and 150.0 ng/ml), enalaprilat (2.99 
ng/ml and 75.8 ng/ml) deviated within±15% of the fresh sample 
concentrations in a battery of stability tests namely, in-injector (22 
h), bench-top (7 h), and repeated four freeze/thaw cycles stability 
(table 13). 
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Table 12: Results of matrix effect of bisoprolol 








% CV 7.0 
% Mean recovery 117.1 
* Abbreviations: Lower limit of quantification (LLOQ), Each value is represented as a mean±SD of 5 observations (n=5), SD: Standard Deviation, 
RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 13: Stability data of bisoprolol, enalapril, enalapril at QCs in human plasma 
Nominal concentration (ng/ml) Stability Stability data 
mean±SD °(n=6) Accuracy (%)• Precision (% CV) 
Bisoprolol-1.51 0 h 1.50±0.32 99.3 2.29 
7 h (bench-Top) 1.50±0.42 99.3 2.36 
22 h (in-injector) 1.50±0.52 99.3 2.60 
3 FT cycles 1.49±0.42 99.3 2.30 
Enalapril–6.28 0 h 6.27±0.37 99.8 3.01 
7 h (bench-Top) 6.27±0.22 99.8 2.71 
22 h (in-injector) 6.26±0.42 99.6 3.36 
3 FT cycles 6.26±0.37 99.6 2.96 
Enalaprilat–2.99 0 h 2.98±0.38 99.6 3.05 
7 h (bench-Top) 2.98±0.45 99.6 3.12 
22 h (in-injector) 2.97±0.67 99.3 3.43 
3 FT cycles 2.96±0.44 98.9 3.11 
Bisoprolol-36.7 0 h 36.6±0.37 99.7 2.07 
7 h (bench-Top) 36.6±0.63 99.7 3.34 
22 h (in-injector) 36.5±0.32 99.4 2.32 
3 FT cycles 36.5±0.57 99.4 3.01 
Enalapril–150.0 0 h 149.9±0.51 99.9 3.15 
7 h (bench-Top) 149.7±0.31 99.8 2.32 
22 h (in-injector) 149.6±0.22 99.7 2.02 
3 FT cycles 149.2±0.64 99.4 3.24 
Enalaprilat–75.8 0 h 75.5±0.53 99.6 3.08 
7 h (bench-Top) 75.3±0.27 99.3 2.04 
22 h (in-injector) 75.3±0.38 99.3 2.54 
3 FT cycles 75.1±0.57 99.0 2.84 
°Back-calculated plasma concentrations; •Mean assayed concentration/mean assayed concentration at 0 h × 100. FT: Freeze-thaw, SD: Standard 
deviation, QC: Quality control, The results were found to be within the assay variability limits during the entire process. 
 
CONCLUSION 
In summary, a highly sensitive, specific, reproducible, rapid and 
high-throughput LC-MS/MS assay was developed and validated to 
quantify bisoprolol and enalapril in the present of enalaprilat in 
human plasma as per the regulatory guidelines. The present method 
involved a simple precipitation method of sample preparation, 
which gave consistent and reproducible recoveries. The sample 
volume requirement supports the possibility to study the full 
pharmacokinetic profile in individuals. Furthermore, the rationale 
for selecting the combination of bisoprolol and enalapril is 
justifiable. Hence, the combination was taken up for developing a 
bioanalytical method development and validation so that further it 
would be useful for performing pharmacokinetic studies. 
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